JW Pharmaceutical Corporation (KRX:001060)
South Korea · Delayed Price · Currency is KRW 26,350
+250 (0.96%)
Jun 10, 2026, 3:30 PM KST
JW Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 789,947 | 775,298 | 719,376 | 748,527 | 684,351 | 606,585 |
Other Revenue | -0 | -0 | -0 | -0 | - | - |
| 789,947 | 775,298 | 719,376 | 748,527 | 684,351 | 606,585 | |
Revenue Growth (YoY) | 9.11% | 7.77% | -3.89% | 9.38% | 12.82% | 10.82% |
Cost of Revenue | 416,355 | 415,984 | 395,878 | 412,984 | 396,397 | 372,209 |
Gross Profit | 373,591 | 359,314 | 323,498 | 335,542 | 287,955 | 234,376 |
Selling, General & Admin | 225,054 | 222,622 | 210,610 | 204,728 | 182,652 | 171,220 |
Research & Development | 44,746 | 45,447 | 36,237 | 33,671 | 33,736 | 19,884 |
Operating Expenses | 274,145 | 271,437 | 240,766 | 238,911 | 227,464 | 203,528 |
Operating Income | 99,447 | 87,877 | 82,733 | 96,631 | 60,490 | 30,848 |
Interest Expense | -4,424 | -4,424 | -10,033 | -12,562 | -9,387 | -7,337 |
Interest & Investment Income | 3,338 | 3,338 | 4,962 | 6,322 | 5,814 | 1,981 |
Earnings From Equity Investments | 2,193 | 2,259 | 1,387 | 621.06 | -955.41 | -1,149 |
Currency Exchange Gain (Loss) | -618.56 | -618.56 | 1,087 | -1,817 | -2,300 | -925.96 |
Other Non Operating Income (Expenses) | -285.78 | -1,126 | 2,253 | -36,102 | 5,425 | -1,191 |
EBT Excluding Unusual Items | 99,650 | 87,305 | 82,390 | 53,095 | 59,088 | 22,227 |
Gain (Loss) on Sale of Investments | 1,578 | 1,578 | 790.9 | 2,830 | -8,908 | -646.8 |
Gain (Loss) on Sale of Assets | -46.76 | -46.76 | 464.91 | -1,088 | 3.28 | -1,048 |
Asset Writedown | - | - | -1,476 | - | -4,821 | - |
Other Unusual Items | - | - | 249.74 | - | - | - |
Pretax Income | 101,181 | 88,836 | 82,420 | 54,836 | 45,362 | 20,533 |
Income Tax Expense | 29,657 | 27,325 | 17,379 | 16,406 | 15,509 | 21,974 |
Earnings From Continuing Operations | 71,524 | 61,511 | 65,040 | 38,430 | 29,853 | -1,441 |
Minority Interest in Earnings | - | - | - | -1,424 | 2,039 | 473.6 |
Net Income | 71,524 | 61,511 | 65,040 | 37,006 | 31,892 | -967.85 |
Preferred Dividends & Other Adjustments | 863.58 | 863.58 | - | - | - | - |
Net Income to Common | 70,661 | 60,648 | 65,040 | 37,006 | 31,892 | -967.85 |
Net Income Growth | 14.58% | -5.43% | 75.75% | 16.04% | - | - |
Shares Outstanding (Basic) | 23 | 23 | 25 | 24 | 23 | 23 |
Shares Outstanding (Diluted) | 23 | 23 | 25 | 24 | 23 | 23 |
Shares Change (YoY) | -9.26% | -7.88% | 3.34% | 2.49% | 0.07% | -0.05% |
EPS (Basic) | 3129.32 | 2676.46 | 2644.00 | 1554.67 | 1373.14 | -41.70 |
EPS (Diluted) | 3129.32 | 2676.46 | 2644.00 | 1554.67 | 1373.14 | -41.70 |
EPS Growth | 22.71% | 1.23% | 70.07% | 13.22% | - | - |
Free Cash Flow | 74,585 | 84,625 | 71,079 | 59,871 | 46,845 | 10,657 |
Free Cash Flow Per Share | 3303.13 | 3734.59 | 2889.49 | 2515.25 | 2016.97 | 459.20 |
Gross Margin | 47.29% | 46.34% | 44.97% | 44.83% | 42.08% | 38.64% |
Operating Margin | 12.59% | 11.34% | 11.50% | 12.91% | 8.84% | 5.08% |
Profit Margin | 8.95% | 7.82% | 9.04% | 4.94% | 4.66% | -0.16% |
Free Cash Flow Margin | 9.44% | 10.91% | 9.88% | 8.00% | 6.84% | 1.76% |
EBITDA | 118,539 | 106,624 | 101,834 | 119,206 | 77,327 | 46,960 |
EBITDA Margin | 15.01% | 13.75% | 14.16% | 15.93% | 11.30% | 7.74% |
D&A For EBITDA | 19,092 | 18,748 | 19,101 | 22,575 | 16,836 | 16,112 |
EBIT | 99,447 | 87,877 | 82,733 | 96,631 | 60,490 | 30,848 |
EBIT Margin | 12.59% | 11.34% | 11.50% | 12.91% | 8.84% | 5.08% |
Effective Tax Rate | 29.31% | 30.76% | 21.09% | 29.92% | 34.19% | 107.02% |
Advertising Expenses | - | 22,691 | 24,252 | 22,690 | 22,673 | 18,416 |